Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Stock Report

| More

Lupin and Boehringer Ingelheim announce Partnership to Develop and Commercialize Novel Oncology Drug to treat KRAS-driven Cancers

Posted On: 2019-09-04 14:10:09

Boehringer Ingelheim and Lupin Limited (Lupin) have announced a licensing, development and commercialization agreement for Lupin's MEK inhibitor compound (LNP3794) as a potential targeted therapy for patients with difficult-to-treat cancers. The partnership aims to develop Lupin's lead MEK inhibitor compound in combination with one of Boehringer Ingelheim's innovative KRAS inhibitors for patients with gastrointestinal and lung cancers harboring a broad range of oncogenic KRAS mutations.

Commenting on the partnership, Nilesh Gupta, Managing Director, Lupin Limited said, "With the success of our second new drug discovery program in oncology, we have made a significant mark in bringing novel treatments to patients. Lupin's MEK Inhibitor program successfully cleared early clinical stages, demonstrating our capabilities in delivering world class innovation. We are proud of the achievements of our team and the capabilities we have built which enable us to further our new drug discovery program. We are delighted to partner with Boehringer Ingelheim in developing treatments that w ill truly benefit patients in need".

Dr. Raj Kamboj, President of Lupin's Novel Drug Discovery and Development (NDDD) stated, "The success of our second NDDD program in Oncology has added to our confidence in bringing highly differentiated and best-in-class innovation from India for patients globally. Carrying forward our founder, Dr. Desh Bandhu Gupta's dream in shaping true innovation, we have delivered a novel treatment from conceptualization to clinical stage development with promising results that can be a potential combination treatment for precision oncology."

"The licensing of Lupin's novel MEK inhibitor enables us to pair with our innovative KRAS inhibitors to develop new combination treatment concepts providing more effect ive and durable responses for patients with cancers driven by activated KRAS who currently have limited treatment options available," said Norbert Kraut, Ph.D., Head of Global Cancer Research at Boehringer Ingelheim. "We believe this collaboration will significantly strengthen our KRAS program. We have developed comprehensive approaches to successfully tackle the oncogenic KRAS - RAF - MEK - ERK pathway from the ground up and this partnership is another key building block in our long-term strategy to bring novel treatments to patients in our quest to defeat intractable cancer types."

The collaboration has a strategic goal to focus on patients with gastrointestinal or lung cancers defined by KRAS mutations, sub-populations that currently need more effective therapeutic options. KRAS mutations occur in 1 in 7 of all human metastatic cancers making it the most frequently mutated cancer-causing gene, with mutation rates of more than 90 perce nt in pancreatic cancers, more than 40 percent in colorectal cancers and more than 30 percent in lung adenocarcinomas. Preclinical data has shown that the combination of Boehringer Ingelheim's novel KRAS inhibitors with MEK inhibitors results in increased anti-tumor activity based on their complementary mechanisms of action in keeping KRAS-driven cancers in check.

Lupin's MEK inhibitors developed as part of its oncology pipeline have shown pre-clinical activity as a single agent as well as in combination. Furthermore, they have also shown early clinical benefit in a small subset of patients. Lupin's Novel Drug Discovery and Development team is focused on building a pipeline of highly differentiated and innovative new chemical entities in the therapeutic areas of oncology, immunology and metabolic disorders. Lupin's NDDD activities were started with the vision to use cutting-edge research in bringing novel molecules that address unmet medical needs in multiple therapeutic areas to market globally.

Lupin will receive an upfront payment of $20 million and potential additional payments for successful achievement of defined clinical, regulatory and commercial milestones for a total deal value of more than $700 million. Additionally, Lu pin will be entitled to receive double-digit roya lties on the sales of the product.

Shares of LUPIN LTD. was last trading in BSE at Rs.733.5 as compared to the previous close of Rs. 740.25. The total number of shares traded during the day was 27442 in over 878 trades.

The stock hit an intraday high of Rs. 745.85 and intraday low of 730.8. The net turnover during the day was Rs. 20268571.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

Ambuja Cements Ltd Q4 CY2019 consolidated PAT lower at Rs. 591.54 crore

ICRA revises long term rating of Indiabulls Housing Finance Limited

GMR Infrastructure Limited announces Strategic Partnership with Groupe ADP for Airports Business

Muthoot Finance Ltd announces pricing of USD 550 million 4.40% notes

UFO Moviez India Ltd board to consider interim dividend on Feb 27, 2020

Dr. Reddy's Laboratories Ltd receives EIR for Duvvada Formulations Plant

Dhanlaxmi Bank Ltd receives RBI nod for appointment of MD & CEO

Sharda Cropchem Ltd Board to consider Second Interim Dividend for FY20

Ambuja Cements Ltd Board recommends Dividend of Rs. 1.50 for CY2019

Plastiblends India Ltd board to consider interim dividend on Feb 25, 2020

Cyient Organizes Blood Donation Drive at its Hyderabad Campus

TCS Named as One of the Fortune Best Big Companies to Work For™ in 2020

India Infoline Finance Ltd raises $400 million

Ambuja Cements Limited appoints Mr. Neeraj Akhoury as new MD and CEO

Garware Technical Fibres Ltd to dispose business undertaking in USA

AstraZeneca Pharma India Ltd launches FDC of Dapagliflozin 10mg + Saxagliptin 5mg film coated tablets (QTERN®)

DCW Limited is the biggest beneficiary of the recently announced anti-dumping duty on imported C-PVC

Jubilant FoodWorks Ltd Board to consider interim dividend on Feb 27, 2020

Jubilant Life Sciences Ltd board to consider interim dividend for FY2020

JK Paper Ltd board to consider interim dividend on Feb 27, 2020

Shri N Baijendra Kumar, CMD, NMDC wins Business Leadership Award

Cyril Amarchand Mangaldas Advises Avenue Supermarts Limited on its INR 4098 Cr. QIP

PVR Ltd board to declare interim dividend on Feb 28, 2020

ICRA assigns ratings to KPIT Technologies Ltd

A.M. Best Affirms A-(Excellent) Rating of The New India Assurance Company Limited

Cipla Ltd board to consider interim dividend for FY2020

SBI Cards IPO to open for subscription on March 2, 2020

Axis Bank to explore long-term strategic partnership with Max Life

Genus Power wins 'Innovative Initiative in the Power Sector', 2020 award for its Smart Metering Pilot project in UAE

JK Cement Ltd board to consider interim dividend on Feb 28, 2020

Shoppers Stop Ltd closes stores at Orion East Mall, Bengaluru and Grant Mall, Chennai

KRBL Ltd board to consider interim dividend for FY2020

Future Lifestyle Fashions Ltd board approves issue of securities to IFC

Trident Ltd board declares interim dividend of Rs. 0.18

Century Plyboards India Ltd forms new subsidiary company

Valiant Organics Ltd board to consider 2nd interim dividend on Feb 28, 2020

Sonata Software Ltd board to consider interim dividend on Feb 26, 2020

JB Chemicals & Pharmaceuticals Ltd board declares interim dividend of Rs. 10

Anuh Pharma Ltd receives CEP for Ambroxol Hydrochloride for EU market

TCS Positioned as a Leader in Application Transformation Services by Everest Group

CARE Ratings Limited updates on ratings of Pitti Engineering Ltd

HGS Recognized on IAOP's 'The 2020 Global Outsourcing 100®' List

Shreyas Shipping & Logistics Ltd announces sale of Vessel 'SSL Kutch'

Redington India Ltd board approves 2nd interim dividend of Rs. 2.80

Cholamandalam Investment and Finance Company Ltd board to consider interim dividend for FY20

Tarini International Ltd updates on SEBI AO Order

Sunteck Realty Ltd has sold 1800 apartments at Sunteck MaxXWorld

Thomas Cook India Ltd board to consider buy back on Feb 26, 2020

Delhi International Airport Ltd offers $150 mn senior secured notes

IndiGo to enable faster ground operations and reduce aircraft turn-around time with WheelTug Systems







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019